NewsBenzingaCanaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79 Canaccord Genuity Maintains Buy on Beam Therapeutics, Raises Price Target to $79 Benzinga 2026.10.29 21:55 (GMT+0) Open on Benzinga Other news Nvidia Shares Rise After Earnings Beat in First Report Since Jensen Huang's Exit NVIDIA Chairman Harvey Jones: Board Has No Intention of Restoring Jensen Huang as CEO Slower Retail Sales Drag on Market SEC reportedly investigating Nvidia amid Huang exit A $3 Billion Reason Why Disney Stock Is in Focus Today Google joins the tech outage trend by announcing it’s not having one